153 related articles for article (PubMed ID: 32369358)
1. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.
Ensan D; Smil D; Zepeda-Velázquez CA; Panagopoulos D; Wong JF; Williams EP; Adamson R; Bullock AN; Kiyota T; Aman A; Roberts OG; Edwards AM; O'Meara JA; Isaac MB; Al-Awar R
J Med Chem; 2020 May; 63(9):4978-4996. PubMed ID: 32369358
[TBL] [Abstract][Full Text] [Related]
2. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Smil D; Wong JF; Williams EP; Adamson RJ; Howarth A; McLeod DA; Mamai A; Kim S; Wilson BJ; Kiyota T; Aman A; Owen J; Poda G; Horiuchi KY; Kuznetsova E; Ma H; Hamblin JN; Cramp S; Roberts OG; Edwards AM; Uehling D; Al-Awar R; Bullock AN; O'Meara JA; Isaac MB
J Med Chem; 2020 Sep; 63(17):10061-10085. PubMed ID: 32787083
[TBL] [Abstract][Full Text] [Related]
3. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
4. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
[TBL] [Abstract][Full Text] [Related]
5. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
Sekimata K; Sato T; Sakai N
Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
7. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K; Sato T; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Honma T; Tanaka A; Shirouzu M; Yokoyama S; Miyazono K; Hashizume Y; Koyama H
Chem Pharm Bull (Tokyo); 2019; 67(3):224-235. PubMed ID: 30828000
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ALK2 with bicyclic pyridyllactams.
Witten MR; Wu L; Lai CT; Kapilashrami K; Pusey M; Gallagher K; Chen Y; Yao W
Bioorg Med Chem Lett; 2022 Jan; 55():128452. PubMed ID: 34780900
[TBL] [Abstract][Full Text] [Related]
9. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
Nguyen MH; Atasoylu O; Wu L; Kapilashrami K; Pusey M; Gallagher K; Lai CT; Zhao P; Barbosa J; Liu K; He C; Zhang C; Styduhar ED; Witten MR; Chen Y; Lin L; Yang YO; Covington M; Diamond S; Yeleswaram S; Yao W
ACS Med Chem Lett; 2022 Jul; 13(7):1159-1164. PubMed ID: 35859885
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
12. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
[TBL] [Abstract][Full Text] [Related]
13. Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of
Murrell E; Tong J; Smil D; Kiyota T; Aman AM; Isaac MB; Watson IDG; Vasdev N
ACS Med Chem Lett; 2021 May; 12(5):846-850. PubMed ID: 34055235
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Conformationally Constrained ALK2 Inhibitors.
González-Álvarez H; Ensan D; Xin T; Wong JF; Zepeda-Velázquez CA; Cros J; Sweeney MN; Hoffer L; Kiyota T; Wilson BJ; Aman A; Roberts O; Isaac MB; Bullock AN; Smil D; Al-Awar R
J Med Chem; 2024 Mar; 67(6):4707-4725. PubMed ID: 38498998
[TBL] [Abstract][Full Text] [Related]
15. Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3.
Muth F; El-Gokha A; Ansideri F; Eitel M; Döring E; Sievers-Engler A; Lange A; Boeckler FM; Lämmerhofer M; Koch P; Laufer SA
J Med Chem; 2017 Jan; 60(2):594-607. PubMed ID: 27977190
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).
Regueiro-Ren A; Xue QM; Swidorski JJ; Gong YF; Mathew M; Parker DD; Yang Z; Eggers B; D'Arienzo C; Sun Y; Malinowski J; Gao Q; Wu D; Langley DR; Colonno RJ; Chien C; Grasela DM; Zheng M; Lin PF; Meanwell NA; Kadow JF
J Med Chem; 2013 Feb; 56(4):1656-69. PubMed ID: 23360431
[TBL] [Abstract][Full Text] [Related]
17. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.
Hudson L; Mui J; Vázquez S; Carvalho DM; Williams E; Jones C; Bullock AN; Hoelder S
J Med Chem; 2018 Aug; 61(16):7261-7272. PubMed ID: 30085668
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel ALK2 inhibitors and their effect on cancer cells.
Kim M; Choi O; Pyo S; Choi SU; Park CH
Biochem Biophys Res Commun; 2017 Oct; 492(1):121-127. PubMed ID: 28782519
[TBL] [Abstract][Full Text] [Related]
19. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
20. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
